Roche is highlighting the benefits of fixed-duration dosing with its bispecific therapies, Lunsumio and Columvi, in the competitive landscape against AbbVie and Genmab’s Epkinly for B-cell lymphomas.
The outcome of ongoing Phase III studies could have a significant impact on market positioning as both companies vie for dominance in this therapeutic area.
Meanwhile, Ken Mulvany has rejoined BenevolentAI, the artificial intelligence drug discovery firm, with a focus on strengthening its foundational strengths.
The UK-based company has initiated a major restructuring plan and intends to delist from Euronext Amsterdam to streamline operations.
Cervomed's shares have dropped by almost 80% following disappointing results from its lead product, neflamapimodin, in a Phase IIb study targeting Lewy body dementia.
Investors are questioning the factors that led to this setback in the CNS disease-focused biotech's development efforts.